Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial

https://doi.org/10.1016/0002-9343(86)90539-5Get rights and content

Abstract

In a six-month, randomized, double-blind study at 14 centers, auranofin (3 mg twice daily) was compared with placebo in the treatment of patients with classic or definite rheumatoid arthritis. All patients had unremitting disease for at least the previous six months and at least three months of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs, oral steroids, and analgesics were allowed throughout the trial. Efficacy was analyzed in 154 patients who received auranofin and 149 who received placebo. To reflect an expanded view of outcome assessment, the measures used included some 20 nontraditional measures of functional performance, pain, global impression, and utility (worth or value) in addition to five standard clinical measures of rheumatoid synovitis (e.g., number of tender joints). The nontraditional measures were mainly in the form of structured questionnaires administered by trained interviewers. To minimize the statistical problem of multiple comparisons, most of the measures were grouped into four composites—clinical (standard measures), functional, global, and pain—and the treatment effect for each composite was tested at the 0.0125 level of significance. Auranofin was superior to placebo in the clinical (p = 0.003), functional (p = 0.001), and global (p = 0.007) composites and trended similarly in the pain composite (p = 0.021). Individual measures within the composites consistently favored auranofin. Other measures, not part of the composites, also favored auranofin, including a patient utility measure designed for this study, the PUMS (p = 0.002). Results confirm the hypothesis that the favorable effect of auranofin on clinical synovitis is accompanied by improvements across a range of outcomes relevant to the patient's quality of life.

References (62)

  • R.A. Deyo

    Measuring functional outcomes in therapeutic trials for chronic disease

    Controlled Clin Trials

    (1983)
  • J.F. Fries

    Toward an understanding of patient outcome measurement

    Arthritis Rheum

    (1983)
  • C Bombardier et al.

    Preference for endpoint measures in clinical trials: results of structured workshops

    J Rheumatol

    (1982)
  • M Liang et al.

    Measuring functional ability in chronic arthritis

    Arthritis Rheum

    (1981)
  • R.F. Meenan et al.

    Measuring health status in arthritis: the arthritis impact measurement scales

    Arthritis Rheum

    (1980)
  • R.F. Meenan et al.

    The arthritis impact measurement scales: further investigations of a health status measure

    Arthritis Rheum

    (1982)
  • R.F. Meenan et al.

    Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure

    Arthritis Rheum

    (1984)
  • J.H. Brown et al.

    The dimensions of health outcomes: a cross-validated examination of health status measurement

    Am J Public Health

    (1984)
  • J.F. Fries et al.

    The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales

    J Rheumatol

    (1982)
  • T Pincus et al.

    Assessment of patient satisfaction in activities of daily living using a modified standard health assessment questionnaire

    Arthritis Rheum

    (1983)
  • R.F. Meenan

    The AIMS approach to health status measurement: conceptual background and measurement properties

    J Rheumatol

    (1982)
  • L.W. Chambers et al.

    The McMaster health index questionnaire as a measure of quality of life for patients with rheumatoid disease

    J Rheumatol

    (1982)
  • A Helewa et al.

    Independent measurement of functional capacity in rheumatoid arthritis

    J Rheumatol

    (1982)
  • D.R. Eberl et al.

    Repeatability and objectivity of various measurements in rheumatoid arthritis: a comparative study

    Arthritis Rheum

    (1976)
  • L.M. Koran

    I. The reliability of clinical methods, data and judgments

    N Engl J Med

    (1975)
  • L.M. Koran

    II. The reliability of clinical methods, data and judgments

    N Engl J Med

    (1975)
  • P.A. Feigenbaum et al.

    The variability of immunologic laboratories test

    J Rheumatol

    (1982)
  • W.W. Buchanan

    Assessment of joint tenderness, grip strength, digital joint circumference and morning stiffness in rheumatoid arthritis

    J Rheumatol

    (1982)
  • J.S. Dickson et al.

    Reproducibility along a 10 cm vertical visual analogue scale

    Ann Rheum Dis

    (1981)
  • R Melzack

    The McGill pain questionnaire: major properties and scoring methods

    Pain

    (1975)
  • R Melzack et al.

    On the language of pain

    Anaesthesiology

    (1971)
  • Cited by (0)

    This work was supported by Smith Kline & French Laboratories.

    View full text